VERU Business Summary

Veru Inc. (VERU) is a late clinical-stage biopharmaceutical company that transitioned into a pure-play drug development firm following the December 2024 divestiture of its commercial FC2 Female Condom business. The company’s current business model centers on the research, development, and future commercialization or licensing of novel medicines targeting cardiometabolic and inflammatory diseases. Its primary value driver is enobosarm, a selective androgen receptor modulator (SARM) being evaluated in the Phase 2b PLATEAU trial to prevent muscle loss and augment fat loss in patients receiving GLP-1 receptor agonists for obesity. A secondary segment focuses on sabizabulin, a microtubule disruptor targeting viral-induced ARDS and atherosclerotic cardiovascular disease. Veru operates in a high-growth landscape alongside competitors such as Eli Lilly, Novo Nordisk, and Viking Therapeutics; however, it distinguishes itself by positioning enobosarm as a complementary "muscle-sparing" therapy rather than a direct competitor to existing weight-loss injectables. The leadership team is anchored by Co-founder Mitchell Steiner, M.D., who serves as Chairman, President, and CEO, bringing extensive experience from his previous roles at OPKO Health and as CEO of Aspen Park Pharmaceuticals. He is supported by Co-founder Harry Fisch, M.D., the current Vice Chairman and Chief Corporate Officer, and Michele Greco, who serves as Chief Financial Officer and Chief Administrative Officer. The scientific direction is led by K. Gary Barnette, Ph.D., as Chief Scientific Officer, while Domingo Rodriguez, M.D., serves as the Chief Medical Officer. The company’s board includes notable figures such as Dr. Mario Eisenberger, a distinguished oncology professor at Johns Hopkins. Veru maintains a strong institutional investor base, with significant positions held by Vanguard Group, BlackRock, and Millennium Management.